What's Happening?
Mass General Brigham has announced the launch of AIwithCare, a new company developed by its researchers to improve clinical trial enrollment through an AI tool called RECTIFIER. This tool, which stands
for RAG-Enabled Clinical Trial Infrastructure for Inclusion Exclusion Review, was created to address the challenges of manually reviewing unstructured electronic health record data. RECTIFIER uses generative AI to screen clinical notes and reports, identifying key eligibility features for clinical trials. The tool has been validated through studies, showing superior accuracy and cost-effectiveness compared to manual methods. It has been deployed across various medical fields, including cardiology and oncology, and has demonstrated the ability to double patient enrollment rates in trials.
Why It's Important?
The introduction of AIwithCare and its RECTIFIER tool is significant for the healthcare industry as it addresses a major bottleneck in clinical research: the manual review of patient data. By automating this process, the tool not only increases the speed and accuracy of patient identification but also reduces the operational burden on clinical teams. This advancement is crucial for enhancing the efficiency of clinical trials, which are essential for developing new treatments and therapies. Moreover, the tool's ability to support equitable research participation by showing no significant differences in eligibility across race, gender, or ethnicity is a step forward in ensuring diverse and inclusive clinical research.
What's Next?
AIwithCare plans to expand the use of RECTIFIER through its AIwithCare Studio platform, allowing other health systems and clinics to adopt similar capabilities. This expansion could lead to broader improvements in clinical trial matching and advanced analytics across the healthcare sector. The success of RECTIFIER at Mass General Brigham sets a precedent for other organizations to implement AI-driven solutions, potentially transforming how clinical trials are conducted and improving access to life-altering therapies.
